Literature DB >> 16173263

Successful treatment of resistant Behçet's disease with etanercept.

F Atzeni, P Sarzi-Puttini, F Capsoni, M Mecchia, M G Marrazza, M Carrabba.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16173263

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  4 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

Review 2.  Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives.

Authors:  Cinzia Rotondo; Giuseppe Lopalco; Florenzo Iannone; Antonio Vitale; Rosaria Talarico; Mauro Galeazzi; Giovanni Lapadula; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2015-06-22       Impact factor: 4.711

Review 3.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711

Review 4.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.